The estimated Net Worth of Theodore L Jr Witek is at least $5.4 Milion dollars as of 20 August 2018. Theodore Witek owns over 8,504 units of Innoviva Inc stock worth over $4,806,680 and over the last 9 years Theodore sold INVA stock worth over $590,987.
Sign up
Theodore Witek INVA stock SEC Form 4 insiders trading
Theodore has made over 5 trades of the Innoviva Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Theodore sold 8,504 units of INVA stock worth $120,076 on 20 August 2018.
The largest trade Theodore's ever made was selling 13,000 units of Innoviva Inc stock on 20 November 2017 worth over $172,770. On average, Theodore trades about 2,682 units every 40 days since 2016. As of 20 August 2018 Theodore still owns at least 247,767 units of Innoviva Inc stock.
You can see the complete history of Theodore Witek stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Theodore Witek's mailing address?
Theodore's mailing address filed with the SEC is 2000 Sierra Point Pkwy #500, Brisbane, CA 94005, USA.
Insiders trading at Innoviva Inc
Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital... oraz Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.
What does Innoviva Inc do?
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
What does Innoviva Inc's logo look like?
Complete history of Theodore Witek stock trades at Innoviva Inc
Innoviva Inc executives and stock owners
Innoviva Inc executives and other stock owners filed with the SEC include:
-
Marianne Zhen,
Chief Accounting Officer -
Marianne Zhen CPA,
Chief Accounting Officer -
Pavel Raifeld C.F.A.,
Chief Exec. Officer -
George Bickerstaff,
Independent Director -
Jules Haimovitz,
Independent Director -
Odysseas Kostas,
Independent Chairman of the Board -
Sarah Schlesinger,
Independent Director -
Mark DiPaolo,
Independent Director -
Pavel Raifeld,
Chief Executive Officer -
Paul Pepe,
Director -
Michael W Aguiar,
President & Chief Exec Officer -
Barbara Gayle Duncan,
Director -
William H Waltrip,
Director -
Theodore L Jr Witek,
Sr. VP & Chief Scientific Off. -
Cathy Friedman,
Director -
James L Tyree,
Director -
Michael E. Faerm,
Sr VP & Chief Business Officer -
George B Abercrombie,
Sr. VP & Chief Comm. Officer -
Patrick G Lepore,
Director -
Eric D Esparbes,
SVP and CFO -
Alexander J Sarissa Capital...,
-
Matthew Ronsheim,
See Remarks -
Geoffrey Hulme,
Interim Principal Exec Officer -
Deborah Birx,
Director -
Plc Gsk,
10% owner -
Derek A Small,
Director -
Sapna Srivastava,
Director -
Margaret Koziel,
Chief Medical Officer -
Stephen Basso,
Chief Financial Officer